Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9

J Biol Chem. 2004 Feb 6;279(6):4750-9. doi: 10.1074/jbc.M304546200. Epub 2003 Nov 20.

Abstract

Flavopiridol, a synthetic flavone closely related to a compound originally isolated from the stem bark of the native Indian plant Dysoxylum binectariferum, has been found to inhibit cyclin-dependent kinases, induce apoptosis, suppress inflammation, and modulate the immune response. Because several genes in which expression is altered by flavopiridol are regulated by NF-kappaB, we propose that this flavone must affect the activation of NF-kappaB. For this report, we investigated the effect of flavopiridol on NF-kappaB activation by various carcinogens and inflammatory agents. Flavopiridol suppressed tumor necrosis factor (TNF)-activation of NF-kappaB in a dose- and time-dependent manner in several cell types, with optimum inhibition occurring upon treatment of cells with 100 nm flavopiridol for 6 h. This effect was mediated through inhibition of IkappaBalpha kinase, phosphorylation, ubiquitination, and degradation of IkappaBalpha (an inhibitor of NF-kappaB), and suppression of phosphorylation, acylation, and nuclear translocation of the p65 subunit of NF-kappaB. Besides TNF, flavopiridol also suppressed NF-kappaB activated by a carcinogen (cigarette smoke condensate), tumor promoters (phorbol myristate acetate and okadaic acid), and an inflammatory agent (H2O2). TNF-induced NF-kappaB-dependent reporter gene transcription was also suppressed by this flavone. NF-kappaB reporter activity induced by TNF receptor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-kappaB-inducing kinase, and IkappaBalpha kinase, were all blocked by flavopiridol but not that activated by p65. Furthermore, flavopiridol suppressed TNF-induced activation of Akt. Flavopiridol also inhibited the expression of the TNF-induced NF-kappaB-regulated gene products cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9. Overall, our results indicated that flavopiridol inhibits activation of NF-kappaB and NF-kappaB-regulated gene expression, which may explain the ability of flavopiridol to suppress inflammation, modulate the immune response, and regulate cell growth.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Carcinogens / pharmacology
  • Cell Line
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology*
  • HL-60 Cells
  • Humans
  • I-kappa B Kinase
  • Inflammation Mediators / pharmacology
  • Jurkat Cells
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / metabolism
  • Phosphorylation
  • Piperidines / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Transcription Factor RelA
  • Transcriptional Activation / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Carcinogens
  • Enzyme Inhibitors
  • Flavonoids
  • Inflammation Mediators
  • NF-kappa B
  • Piperidines
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • alvocidib
  • Protein Serine-Threonine Kinases
  • CHUK protein, human
  • I-kappa B Kinase
  • IKBKB protein, human
  • IKBKE protein, human